Dr. Schuster Dicsusses CAR T-Cell Therapy in DLBCL

Video

Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses CAR T-cell therapy in diffuse large B-cell lymphoma.

Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

The primary analysis of the phase II global JULIET study was presented at the 2017 ASH Annual Meeting. This study assessed tisagenlecleucel (Kymriah) in adult patients with relapsed/refractory DLBCL, demonstrating an overall response rate of 53.1%. Tisagenlecleucel is currently approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

Schuster says that the results that lead to the FDA approval of tisagenlecleucel in ALL inspired him to look at the CAR T-cell therapy in patients with DLBCL. About one-third of patients with DLBCL have no chance of remission with the currently available therapies, so Schuster hopes that this unmet need can be resolved with CAR T-cell therapy.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.